13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388325
Total reported value
$1.7B
$1.7B
24 檔
35.0%
The Q4 2025 SEC filing reveals that Novo Holdings A/S held a total portfolio value of $1.7B, covering 24 public equity positions.
In Q4 2025, Novo Holdings A/S adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 4 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including BN, EWTX, ASML) accounted for 35.0% of total reported equity market value during Q4 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BN | Brookfield CORP | Stock-Financials | 12.46% | -2.78% | +50.00% | |
| 2 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 10.31% | -1.03% | — | |
| 3 | ASML | ASML Holding N.V. | Stock-Tech | 9.47% | +0.81% | -21.87% | |
| 4 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 7.75% | -2.27% | — | |
| 5 | CRM | Salesforce Inc | Stock-Tech | 6.79% | -2.37% | — | |
| 6 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 5.87% | -1.69% | — | |
| 7 | VRDN | Viridian Therapeutics Inc | Stock-Other | 5.75% | -0.89% | — | |
| 8 | MPLT | Maplight Therapeutics Inc | Stock-Other | 5.03% | +1.60% | — | |
| 9 | ZBIO | Zenas Biopharma Inc | Stock-Other | 4.09% | — | -27.50% | |
| 10 | PHVS | Pharvaris N.V. | Stock-Other | 3.77% | -1.20% | — | |
| 11 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.34% | -3.07% | EXIT | |
| 12 | PCVX | Vaxcyte Inc | Stock-Other | 3.28% | -1.35% | — | |
| 13 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.05% | -3.02% | EXIT | |
| 14 | AVBP | Arrivent Biopharma Inc | Stock-Other | 3.03% | -0.60% | — | |
| 15 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 2.93% | -1.19% | — | |
| 16 | INSM | Insmed Inc | Stock-Healthcare | 2.70% | +0.75% | NEW | |
| 17 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.53% | -0.87% | — | |
| 18 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.13% | -0.24% | +82.54% | |
| 19 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.91% | -0.59% | — | |
| 20 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.77% | -1.12% | +3.77% | |
| 21 | VALN | Valneva Se - Adr | Stock-Other | 1.58% | -0.54% | EXIT | |
| 22 | LNZA | Lanzatech Global Inc | Stock-Other | 0.17% | -0.15% | — | |
| 23 | MQ | Marqeta Inc-a | Stock-Other | 0.16% | +0.27% | — | |
| 24 | IOBTQ | Io Biotech Inc | Stock-Other | 0.12% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | +4.7% | — | Unchanged |
| 2 | VRDN | Viridian Therapeutics Inc | +2.4% | — | Unchanged |
| 3 | BN | Brookfield CORP | +2.2% | +50.00% | Add |
| 4 | APGE | Apogee Therapeutics Inc | +2.1% | +14.00% | Add |
| 5 | MIRM | Mirum Pharmaceuticals Inc | +1.8% | — | Unchanged |
| 6 | CRM | Salesforce Inc | +1.8% | — | Unchanged |
| 7 | CRNX | Crinetics Pharmaceuticals In | +1.5% | — | Unchanged |
| 8 | ZBIO | Zenas Biopharma Inc | +1.2% | -27.50% | Trim |
| 9 | PCVX | Vaxcyte Inc | +1.2% | — | Unchanged |
| 10 | FDMT | 4d Molecular Therapeutics In | +1% | +82.54% | Add |
| 11 | PHVS | Pharvaris N.V. | +1% | — | Unchanged |
| 12 | INSM | Insmed Inc | +0.8% | — | Unchanged |
| 13 | BMRN | Biomarin Pharmaceutical Inc | +0.8% | — | Unchanged |
| 14 | AVBP | Arrivent Biopharma Inc | +0.7% | — | Unchanged |
| 15 | CLDX | Celldex Therapeutics Inc | +0.5% | — | Unchanged |
| 16 | BBOT | Bridgebio Oncology Therapeut | +0.5% | — | Unchanged |
| 17 | ASML | ASML Holding N.V. | +0.4% | -21.87% | Trim |
| 18 | IOBTQ | Io Biotech Inc | +0.1% | — | Unchanged |
| 19 | MQ | Marqeta Inc-a | 0% | — | Unchanged |
| 20 | BABA | Alibaba Group Holding-sp Adr | 0% | — | Unchanged |
| 21 | LNZA | Lanzatech Global Inc | -0.1% | — | Unchanged |
| 22 | ELVN | Enliven Therapeutics Inc | -0.1% | +3.77% | Add |
| 23 | VALN | Valneva Se - Adr | -0.3% | -1.71% | Trim |
| 24 | VTI | Vanguard Total Stock Mkt ETF | — | EXIT | Sold out |
| 25 | ✓ | Merus N V | — | EXIT | Sold out |
| 26 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 27 | RXRX | Recursion Pharmaceuticals-a | — | EXIT | Sold out |
| 28 | DMRA | Damora Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Novo Holdings A/S reported a total U.S. public equity portfolio value of $1.7B across 24 disclosed positions in Q4 2025.
During Q4 2025, Novo Holdings A/S's top holdings by market value included BN (12.5%)、EWTX (10.3%)、ASML (9.5%). The largest single position, BN, represented 12.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
MPLT
市值: $64.8M
Top Position Liquidated / Trimmed
VTI
前期市值: $340.8M
In Q4 2025, Novo Holdings A/S made 12 total portfolio adjustments, initiating 1 new buys, adding to 4 positions, trimming 3 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.